News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Benitec Biopharma Inc. (BNTC) is showing a near-term strong sentiment that could challenge persistent mid and long-term weakness, with a mid-channel oscillation pattern in play. Quantitative analysis suggests an exceptional 48.8:1 risk-reward short setup. The article details institutional trading strategies, including position trading, momentum …
This article provides a brief overview of Benitec Biopharma Inc.'s (NASDAQ: BNTC) financial information available on TradingView, specifically mentioning revenue breakdown through segments and regional performance. It highlights where to find fundamental data, statements, statistics, dividends, and earnings. The article also lists the various …
This article provides a technical analysis of Benitec Biopharma Inc (BNTC), detailing its current price momentum score of 4.07 and its ranking within the Biotechnology & Medical Research industry. It identifies the stock's support at 10.59 and resistance at 13.33, suggesting suitability for range-bound …
This article provides a risk assessment for Benitec Biopharma Inc (BNTC), highlighting its volatility, financial metrics, and investment risks. BNTC's current risk assessment score is 2.97, ranking it 169 out of 385 in the Biotechnology & Medical Research industry, with a beta of 0.28 …
This article provides a valuation analysis for Benitec Biopharma Inc (BNTC), noting its current valuation score is 8.53, ranking 116th in its industry. The company's P/E ratio is -13.06, which is significantly below its recent high. Key valuation metrics like P/B, P/S, and P/CF …
This article provides historical data on dividends and stock splits for Benitec Biopharma Inc (BNTC). It indicates that BNTC has not distributed any dividends in the past five years. The article also lists multiple merger events that occurred on July 25, 2023, with a …
This article provides a detailed cash flow statement for Benitec Biopharma Inc (BNTC), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures and year-over-year percentage changes across various cash flow components. The article also includes an FAQ section …
Benitec Biopharma Inc (BNTC) is a clinical-stage biotechnology company with strong fundamentals, a high growth potential, and considered fairly valued within the Biotechnology & Medical Research industry. Analysts currently rate BNTC as a "Buy" with a target price of $25.80, indicating a significant upside. …
Benitec Biopharma Inc (BNTC) has an institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The current institutional shareholding proportion is 96.50%, a 36.40% increase quarter-over-quarter. The largest institutional holder is Bill Nygren | OAKMX, although their holdings decreased …
This article provides an in-depth analysis of Benitec Biopharma Inc. (NASDAQ: BNTC), highlighting weak sentiment across all horizons which supports a short bias. It details an exceptional risk-reward short setup positioning and outlines institutional trading strategies based on AI models, including position, momentum breakout, …
Search by ticker symbol or company name and select a result to open its chart.